AIM IMMUNOTECH INC. overview

OCALA, Fla., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation March 24th @ 3:00 PM ET Location https://zoom.us/webinar/register/WN_y7LDL2ROTQqvz3iOVkINMw About The Investor Summit The Investor Summit (formerly MicroCap Conference) is an exclusive,...

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers' Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects OCALA, FL / ACCESSWIRE / December 24, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that the post-COVID-19 "Long Hauler" portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a...

DGAP-News: AIM ImmunoTech Inc. / Key word(s): Miscellaneous AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands 22.09.2020 / 17:52 The issuer is solely responsible for the content of this announcement. Median survival approximately two-fold higher in Ampligen arm compared to historical controls; AIM to seek FDA Fast Track designation and orphan drug status in late stage pancreatic cancer...

Median survival approximately two-fold higher in Ampligen arm compared to historical controls; AIM to seek FDA Fast Track designation and orphan drug status in late stage pancreatic cancer OCALA, FL / ACCESSWIRE / September 22, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program (EAP) conducted at Erasmus University Medical Center in the Netherlands. Prof. Casper van...

OCALA, FL / ACCESSWIRE / September 16, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced that recruitment has begun in Roswell Park Comprehensive Cancer Center's Phase 1/2a clinical study of the effectiveness of rintatolimod (Ampligen) in combination with interferon alpha-2b in treating cancer patients with mild or moderate COVID-19 infection, which is caused by the SARS-CoV-2 virus. Roswell Park has reported through the national clinical-trials database ClinicalTrials.gov that...

OCALA, FL / ACCESSWIRE / September 10, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced that the company will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020. Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to present on Monday, September 14 at 5:00 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here . About AIM...

OCALA, FL / ACCESSWIRE / September 8, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), today announced that Thomas K. Equels, CEO of AIM ImmunoTech, will participate in a virtual panel titled, "New Approaches to COVID-19: Hidden Breakthroughs," being held on Thursday, September 10, 2020 at 1:00 p.m. ET. The virtual panel discussion will also include: Dr. David Jin, President and CEO of Avalon Globlocare Corp. (NASDAQ:AVCO); Jeff Wolf, CEO of Heat Biologics, Inc. (NASDAQ:HTBX); Dr. Jennifer Bath,...

OCALA, FL / ACCESSWIRE / August 27, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) is pleased to announce that it has identified an effective in vitro model at The Institute for Antiviral Research at Utah State University for testing Ampligen, a dsRNA TLR3 agonist, and the results show that Ampligen was able to decrease SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels. This result supports AIM's goal of developing an intranasal prophylactic...